Shares of United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $642.69.
Several brokerages have recently commented on UTHR. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Morgan Stanley lifted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research report on Thursday.
Read Our Latest Analysis on United Therapeutics
United Therapeutics Price Performance
Shares of NASDAQ:UTHR opened at $541.51 on Friday. The business’s fifty day moving average price is $513.75 and its two-hundred day moving average price is $540.45. United Therapeutics has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The stock has a market capitalization of $23.23 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 3.86 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $6.41 earnings per share. Research analysts expect that United Therapeutics will post 26.40 EPS for the current fiscal year.
Key United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics settled all six patent and antitrust disputes with Liquidia, reducing litigation uncertainty surrounding Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement also limits YUTREPIA’s label, particularly by excluding the pulmonary hypertension associated with interstitial lung disease indication, which may protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
- Positive Sentiment: The settlement calls for Liquidia to make approximately $380.7 million in payments, providing United Therapeutics with financial compensation for resolving the disputes. The deal also gives investors more visibility into the future competitive landscape. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
- Positive Sentiment: Jefferies raised its price target for United Therapeutics to $728. Other analysts also remain constructive: the stock carries a “Moderate Buy” consensus rating and an average target of $627.31, above the recent trading level. UTHR Price Target Raised to $728 at Jefferies
- Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her ownership by 2.84%. The transaction was disclosed in an SEC filing, but the remaining stake is substantial and the sale alone does not establish a change in business outlook. United Therapeutics CEO Stock Sale SEC Filing
Insider Activity at United Therapeutics
In other news, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total value of $4,689,085.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $25,519,921.40. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total transaction of $5,129,905.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $175,195,975.57. This trade represents a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 383,728 shares of company stock valued at $198,367,306. Company insiders own 8.60% of the company’s stock.
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Toth Financial Advisory Corp boosted its stake in United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics in the second quarter valued at $30,000. Caitlin John LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at $37,000. International Assets Investment Management LLC increased its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new position in shares of United Therapeutics in the second quarter valued at about $81,000. 94.08% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Featured Stories
- Five stocks we like better than United Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
